Search Results - "Helmy, Joanna"

Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial by Sriranjan, Rouchelle, Zhao, Tian Xiao, Tarkin, Jason, Hubsch, Annette, Helmy, Joanna, Vamvaka, Evangelia, Jalaludeen, Navazh, Bond, Simon, Hoole, Stephen P, Knott, Philip, Buckenham, Samantha, Warnes, Victoria, Bird, Nick, Cheow, Heok, Templin, Heike, Cacciottolo, Paul, Rudd, James H F, Mallat, Ziad, Cheriyan, Joseph

“…IntroductionInflammation plays a critical role in the pathogenesis of atherosclerosis, the leading cause of ischaemic heart disease (IHD). Studies in…”
Get full text

Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study by Cacciottolo, Paul J, Kostapanos, Michalis S, Hernan Sancho, Elena, Pavey, Holly, Kaloyirou, Fotini, Vamvaka, Evangelia, Helmy, Joanna, Hubsch, Annette, McEniery, Carmel M, Wilkinson, Ian B, Cheriyan, Joseph

“…IntroductionElevated low-density lipoprotein cholesterol (LDL-C) is a strong independent risk predictor of cardiovascular (CV) events, while interventions to…”
Get full text

Abstract 4144964: Low-Dose IL-2 Lowers Arterial Inflammation and Trends Towards Lower MACE in patients with ACS: The results of the IVORY trial and IVORY FINALE study by Sriranjan Rothwell, Rouchelle, Zhao, Tian, Hoole, Stephen, Bond, Simon, Tarkin, Jason, hubsch, Annette, Helmy, Joanna, Bumanlag-Amis, Elaine, Jalaludeen, Navazh, Templin, Heike, Brubert, Jacob, Krishnan, Unni, O'Brien, James, Rudd, James, Cheriyan, Joseph, Mallat, Ziad

“…Abstract only Major adverse cardiovascular (CV) events (MACE) occur in a substantioal percentage of individuals following acute coronary syndromes (ACS),…”
Get full text

THE EFFECTS OF ALIROCUMAB VERSUS EZETIMIBE ON TOP OF STATINS ON VASCULAR INFLAMMATION AND FUNCTION by Cacciottolo, Paul J., Kostapanos, Michalis, Hubsch, Annette, Vamvaka, Evangelia, Kaloyirou, Fotini, Helmy, Joanna, Sancho, Elena H., Pavey, Holly, Maki-Petaja, Kaisa, Wilkinson, Ian, Cheriyan, Joseph

Get full text

Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial by Zhao, Tian Xiao, Kostapanos, Michalis, Griffiths, Charmaine, Arbon, Emma L, Hubsch, Annette, Kaloyirou, Fotini, Helmy, Joanna, Hoole, Stephen P, Rudd, James H F, Wood, Graham, Burling, Keith, Bond, Simon, Cheriyan, Joseph, Mallat, Ziad

“…IntroductionInflammation and dysregulated immune responses play a crucial role in atherosclerosis, underlying ischaemic heart disease (IHD) and acute coronary…”
Get full text

Low-dose i nterleukin 2 for the reduction of v ascular inflammati o n in acute corona ry syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial by Sriranjan, Rouchelle, Zhao, Tian Xiao, Tarkin, Jason, Hubsch, Annette, Helmy, Joanna, Vamvaka, Evangelia, Jalaludeen, Navazh, Bond, Simon, Hoole, Stephen P, Knott, Philip, Buckenham, Samantha, Warnes, Victoria, Bird, Nick, Cheow, Heok, Templin, Heike, Cacciottolo, Paul, Rudd, James H F, Mallat, Ziad, Cheriyan, Joseph

“…Inflammation plays a critical role in the pathogenesis of atherosclerosis, the leading cause of ischaemic heart disease (IHD). Studies in preclinical models…”
Get full text

Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease by Zhao, Tian X, Sriranjan, Rouchelle S, Tuong, Zewen Kelvin, Lu, Yuning, Sage, Andrew P, Nus, Meritxell, Hubsch, Annette, Kaloyirou, Fotini, Vamvaka, Evangelia, Helmy, Joanna, Kostapanos, Michalis, Jalaludeen, Navazh, Klatzmann, David, Tedgui, Alain, Rudd, James H F, Horton, Sarah J, Huntly, Brian J P, Hoole, Stephen P, Bond, Simon P, Clatworthy, Menna R, Cheriyan, Joseph, Mallat, Ziad

“…Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease This phase 1b/2a, randomized, double-blind, placebo-controlled, dose-escalation…”
Get more information